Merit Medical Systems (MMSI) Aperçu de l'action
Merit Medical Systems, Inc. conçoit, développe, fabrique et commercialise des produits médicaux à usage unique pour des procédures interventionnelles, diagnostiques et thérapeutiques aux États-Unis, en Chine, au Japon, en Allemagne, en France, au Royaume-Uni et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 3/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
MMSI ont passé avec succès nos contrôles de risques.
MMSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merit Medical Systems, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$73.04 |
| Plus haut sur 52 semaines | US$94.75 |
| Plus bas sur 52 semaines | US$59.74 |
| Bêta | 0.51 |
| Variation sur 1 mois | 9.11% |
| Variation sur 3 mois | 4.19% |
| Variation sur 1 an | -13.00% |
| Variation sur 3 ans | -11.35% |
| Variation sur 5 ans | 15.41% |
| Évolution depuis l'introduction en bourse | 1,308.91% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 03
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.
Mise à jour du récit • Jun 19
MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.Mise à jour du récit • Jun 04
MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Recent updates
Mise à jour du récit • Jul 03
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.Mise à jour du récit • Jun 19
MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.Mise à jour du récit • Jun 04
MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Nouveau récit • May 16
Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 02
Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking Alpha
Nouveau récit • May 01
Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 24
MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.Mise à jour du récit • Apr 08
MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential
Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.Article d’analyse • Dec 31
We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Article d’analyse • Jul 14
Calculating The Fair Value Of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Key Insights The projected fair value for Merit Medical Systems is US$80.02 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • Jun 29
If EPS Growth Is Important To You, Merit Medical Systems (NASDAQ:MMSI) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • May 21
Risks To Shareholder Returns Are Elevated At These Prices For Merit Medical Systems, Inc. (NASDAQ:MMSI)
With a price-to-earnings (or "P/E") ratio of 47.8x Merit Medical Systems, Inc. ( NASDAQ:MMSI ) may be sending very...Article d’analyse • May 07
We Take A Look At Why Merit Medical Systems, Inc.'s (NASDAQ:MMSI) CEO Has Earned Their Pay Packet
Key Insights Merit Medical Systems will host its Annual General Meeting on 14th of May CEO Fred Lampropoulos' total...Article d’analyse • Apr 11
Merit Medical Systems' (NASDAQ:MMSI) Returns On Capital Are Heading Higher
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Article d’analyse • Mar 30
Is Now An Opportune Moment To Examine Merit Medical Systems, Inc. (NASDAQ:MMSI)?
While Merit Medical Systems, Inc. ( NASDAQ:MMSI ) might not have the largest market cap around , it received a lot of...Article d’analyse • Mar 18
Here's Why We Think Merit Medical Systems (NASDAQ:MMSI) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Seeking Alpha • Mar 16
Merit Medical: A Success Story That Keeps Getting Better
Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking AlphaArticle d’analyse • Mar 06
A Look At The Fair Value Of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Key Insights Merit Medical Systems' estimated fair value is US$100 based on 2 Stage Free Cash Flow to Equity With...Article d’analyse • Feb 10
Merit Medical Systems (NASDAQ:MMSI) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Article d’analyse • Jan 17
Why We're Not Concerned About Merit Medical Systems, Inc.'s (NASDAQ:MMSI) Share Price
With a price-to-earnings (or "P/E") ratio of 49.6x Merit Medical Systems, Inc. ( NASDAQ:MMSI ) may be sending very...Seeking Alpha • Jan 08
Merit Medical Systems: Solid Execution, Stretched Valuations
Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking? An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Dec 23
Returns Are Gaining Momentum At Merit Medical Systems (NASDAQ:MMSI)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Article d’analyse • Dec 11
Is Now An Opportune Moment To Examine Merit Medical Systems, Inc. (NASDAQ:MMSI)?
While Merit Medical Systems, Inc. ( NASDAQ:MMSI ) might not have the largest market cap around , it saw a decent share...Article d’analyse • Nov 29
Is Now The Time To Put Merit Medical Systems (NASDAQ:MMSI) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Nov 02
Merit Medical Systems, Inc. (NASDAQ:MMSI) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
It's been a good week for Merit Medical Systems, Inc. ( NASDAQ:MMSI ) shareholders, because the company has just...Article d’analyse • Nov 01
Is Merit Medical Systems (NASDAQ:MMSI) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 17
Merit Medical Systems - Impressive Momentum
Summary Merit Medical Systems has shown strong operating momentum this year, driven by organic growth and strategic acquisitions. Founder Fred Lampropoulos plans to retire by the end of 2025, as a well-planned succession alleviates concerns on that front. Recent acquisitions, including EndoGastric Solutions and Cook's Medical portfolio, enhance product offerings but are priced into the current high valuation. Despite positive momentum and trial results, the stock's high valuation warrants a cautious, wait-and-see approach. Read the full article on Seeking AlphaArticle d’analyse • Sep 17
The Price Is Right For Merit Medical Systems, Inc. (NASDAQ:MMSI)
Merit Medical Systems, Inc.'s ( NASDAQ:MMSI ) price-to-earnings (or "P/E") ratio of 49.4x might make it look like a...Rendement pour les actionnaires
| MMSI | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | 2.8% | -2.7% | 0.8% |
| 1Y | -13.0% | -20.6% | 20.5% |
Rendement vs Industrie: MMSI a dépassé le secteur US Medical Equipment qui a rapporté -20.6 % au cours de l'année écoulée.
Rendement vs marché: MMSI a sous-performé le marché US qui a rapporté 20.5 % au cours de l'année écoulée.
Volatilité des prix
| MMSI volatility | |
|---|---|
| MMSI Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: MMSI n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de MMSI ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1987 | 7,500 | Martha Aronson | www.merit.com |
Merit Medical Systems, Inc. conçoit, développe, fabrique et commercialise des produits médicaux à usage unique pour des procédures interventionnelles, diagnostiques et thérapeutiques aux États-Unis, en Chine, au Japon, en Allemagne, en France, au Royaume-Uni et dans le monde entier. Elle opère à travers deux segments, Cardiovascular et Endoscopy. La société propose des kits de micropuncture, des aiguilles angiographiques, des gaines, des fils guides et des produits de sécurité ; des produits d'intervention périphérique comprenant des produits d'angiographie, de drainage, des systèmes d'administration et des produits d'embolothérapie ; des produits d'oncologie, tels que des produits et accessoires de biopsie des tissus mous ; des produits d'intervention cardiaque comprenant l'accès cardiaque, l'angiographie, l'électrophysiologie et la gestion du rythme cardiaque, la gestion des fluides, la surveillance hémodynamique, l'hémostase et les produits d'intervention ; et des produits pour la colonne vertébrale, y compris les systèmes d'augmentation vertébrale, d'ablation par radiofréquence et de biopsie osseuse.
Merit Medical Systems, Inc. Résumé des fondamentaux
| MMSI statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$4.24b |
| Bénéfices(TTM) | US$139.34m |
| Recettes(TTM) | US$1.54b |
31.3x
Ratio P/E2.8x
Ratio P/SLe site MMSI est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MMSI compte de résultat (TTM) | |
|---|---|
| Recettes | US$1.54b |
| Coût des recettes | US$791.39m |
| Marge brute | US$751.05m |
| Autres dépenses | US$611.71m |
| Les revenus | US$139.34m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 30, 2026
| Résultat par action (EPS) | 2.34 |
| Marge brute | 48.69% |
| Marge bénéficiaire nette | 9.03% |
| Ratio dettes/capitaux propres | 45.2% |
Quelles ont été les performances à long terme de MMSI?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/15 13:44 |
| Cours de l'action en fin de journée | 2026/07/15 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Merit Medical Systems, Inc. est couverte par 22 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Baird |
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |